Skip to main content
Log in

Lack of MGMT promoter hypermethylation in hemangiopericytomas of the central nervous system

  • Letter to the Editor
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Chang IW, Lin JW, Wu YT (2011) The status of MGMT protein expression is a prognostic factor for meningeal hemangiopericytoma: a clinicopathologic and immunohistochemical study of 12 cases at a single institution. J Neurooncol 105:563–572

    Article  PubMed  CAS  Google Scholar 

  2. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM (2011) Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 117:4939–4947

    Article  PubMed  CAS  Google Scholar 

  3. Brokinkel B, Fischer BR, Peetz-Dienhart S, Ebel H, Sepehrnia A, Rama B, Albert FK, Stummer W, Paulus W, Hasselblatt M (2010) MGMT promoter methylation status in anaplastic meningiomas. J Neurooncol 100:489–490

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Martin Hasselblatt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brokinkel, B., Peetz-Dienhart, S., Keyvani, K. et al. Lack of MGMT promoter hypermethylation in hemangiopericytomas of the central nervous system. J Neurooncol 110, 303–304 (2012). https://doi.org/10.1007/s11060-012-0967-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-012-0967-4

Keywords

Navigation